TriSalus Life Sciences, Inc.
TLSI
$5.73
$0.081.42%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 29.43M | 26.89M | 24.74M | 21.98M | 18.51M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.43M | 26.89M | 24.74M | 21.98M | 18.51M |
| Cost of Revenue | 4.10M | 3.47M | 3.05M | 2.91M | 2.61M |
| Gross Profit | 25.33M | 23.42M | 21.68M | 19.07M | 15.91M |
| SG&A Expenses | 43.81M | 42.04M | 42.31M | 40.73M | 36.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 65.61M | 68.02M | 73.16M | 73.67M | 68.63M |
| Operating Income | -36.18M | -41.13M | -48.42M | -51.68M | -50.12M |
| Income Before Tax | -30.05M | -55.58M | -54.60M | -64.24M | -59.30M |
| Income Tax Expenses | 6.00K | 8.00K | 11.00K | 17.00K | 9.00K |
| Earnings from Continuing Operations | -30.06 | -55.59 | -54.62 | -64.26 | -59.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.06M | -55.59M | -54.62M | -64.26M | -59.31M |
| EBIT | -36.18M | -41.13M | -48.42M | -51.68M | -50.12M |
| EBITDA | -35.43M | -40.39M | -47.69M | -51.00M | -49.44M |
| EPS Basic | -1.33 | -2.51 | -2.53 | -38.15 | -38.12 |
| Normalized Basic EPS | -1.04 | -1.49 | -2.23 | -22.18 | -22.28 |
| EPS Diluted | -1.33 | -2.51 | -2.53 | -38.15 | -38.12 |
| Normalized Diluted EPS | -1.04 | -1.49 | -2.23 | -22.18 | -22.28 |
| Average Basic Shares Outstanding | 101.28M | 96.96M | 83.63M | 60.17M | 53.02M |
| Average Diluted Shares Outstanding | 101.28M | 96.96M | 83.63M | 60.17M | 53.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |